针对CK1δ和CK1ε作为清细胞脏细胞癌的新疗法
Yu-Chen Lin1,2, Ding-Ping Sun3,4, Tsung-Han Hsieh5
1Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Pharmacology
|July 2, 2024
概括
凯激酶1delta (CK1δ) 和epsilon (CK1ε) 的表达增加与癌的存活率较低相关. 抑制CK1δ/ε显示出作为细胞癌 (RCC) 的新治疗策略的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 癌,特别是细胞癌 (RCC),是一个重大的全球卫生挑战.
- 目前对RCC的治疗方法虽然先进,但缺乏可靠的生物标志物,并且提供有限的疾病控制持续时间.
- 氨酸激酶1delta (CK1δ) 和epsilon (CK1ε) 在RCC进展中的作用尚不清楚.
研究的目的:
- 研究CK1δ和CK1ε在细胞癌 (RCC) 进展中的作用.
- 评估CK1δ/ε作为RCC治疗的治疗点的潜力.
主要方法:
- 对微阵列和TCGA数据集的分析,以将CK1δ/ε表达与RCC进展相关联.
- 使用MTT/SRB试验对CK1δ/ε抑制剂 (SR3029) 的体外评估.
- 流式细胞计和西式涂抹以分析亡诱导和细胞循环效应.
主要成果:
- 与正常脏样本相比,CSNK1D (CK1δ) 和CSNK1E (CK1ε) 的基因表达在透明细胞RCC (ccRCC) 组织中显著增加.
- 较高的CK1δ/ε表达与ccRCC患者的生存率降低相关.
- CK1δ/ε抑制剂SR3029有效地抑制了ccRCC细胞的活力和增殖,诱导了不依赖于VHL缺乏状态的细胞亡.
结论:
- 在清细胞细胞癌 (ccRCC) 的进展中,CK1δ和CK1ε起着至关重要的作用.
- CK1δ/ε抑制剂代表了对ccRCC患者的有前途的新治疗途径.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
15:43Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
Published on: January 7, 2013
18.1K
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
